glp 1 patient education GLP-1 for Weight Loss and Diabetes Indications for GLP-1/GIP RA Summary

A previous study indicated that treatment with the GLP-1 agonist liraglutide (subcutaneously at a dose gradually titrated from 0.6 to 3 mg) in bipolar and mood disorder depression patients could result in an improvement in cognitive function and an alleviation of depressive pathological symptoms ( Considering this evidence, increasing neurogenesis in the brain through the GLP-1 pathway may provide a novel approach for improving depressive-like behavior in patients with depression

Sofwave can be used as a standalone rejuvenation treatment or as part of a longer-term regenerative plan to maintain skin quality as the face continues to age

Tirzepatide can interact with oral contraceptives making them temporarily less effective [archived link]

Side effects and therapeutic response are not the same measurement

You will discuss your goals with the doctor and receive an order for blood work if you are a good candidate and wish to move forward

States with no obesity GLP-1 coverage: Most remaining states including Texas, Florida, Ohio, New Jersey, and Georgia do not cover GLP-1s for obesity at all